
EKSO Stock Forecast & Price Target
EKSO Analyst Ratings
Bulls say
Ekso Bionics Holdings Inc. reported a notable recovery in its financial performance for the third quarter of 2025, with total revenues reaching $4.22 million, reflecting a year-over-year growth of 105% compared to $2.06 million in the previous quarter. Additionally, the company experienced a significant improvement in gross margins, rising to 60.3%, up from 39.8% in the prior quarter. This positive trajectory in revenue and profitability, along with a potential merger announcement, indicates a strong operational rebound and strategic positioning within the exoskeleton technology market.
Bears say
Ekso Bionics Holdings Inc experienced a revenue miss in prior quarters, attributed to two significant order delays from enterprise sales that collectively impacted revenue by $1.5 million. For the third quarter of 2025, the company reported revenues of $4.23 million alongside a net loss of $0.54 per share, which highlights ongoing financial challenges despite slightly exceeding consensus expectations. The downgrade in rating reflects concerns about the company's ability to secure timely orders, signaling potential instability in its sales pipeline and overall performance.
This aggregate rating is based on analysts' research of Ekso Bionics Hlds and is not a guaranteed prediction by Public.com or investment advice.
EKSO Analyst Forecast & Price Prediction
Start investing in EKSO
Order type
Buy in
Order amount
Est. shares
0 shares